276 related articles for article (PubMed ID: 11592053)
1. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
[TBL] [Abstract][Full Text] [Related]
2. Mapping of ligand binding sites of the cholecystokinin-B/gastrin receptor with lipo-gastrin peptides and molecular modeling.
Lutz J; Romano-Götsch R; Escrieut C; Fourmy D; Mathä B; Müller G; Kessler H; Moroder L
Biopolymers; 1997 Jun; 41(7):799-817. PubMed ID: 9128441
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
6. CCK-A- and CCK-B-like receptors in the gallbladder and stomach of the alligator (Alligator mississippiensis).
Oliver AS; Vigna SR
Gen Comp Endocrinol; 1997 Jan; 105(1):91-101. PubMed ID: 9000471
[TBL] [Abstract][Full Text] [Related]
7. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
[TBL] [Abstract][Full Text] [Related]
8. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
Gigoux V; Maigret B; Escrieut C; Silvente-Poirot S; Bouisson M; Fehrentz JA; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy AD
Protein Sci; 1999 Nov; 8(11):2347-54. PubMed ID: 10595537
[TBL] [Abstract][Full Text] [Related]
9. Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin.
Foucaud M; Archer-Lahlou E; Marco E; Tikhonova IG; Maigret B; Escrieut C; Langer I; Fourmy D
Regul Pept; 2008 Jan; 145(1-3):17-23. PubMed ID: 17961734
[TBL] [Abstract][Full Text] [Related]
10. Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor.
De Luca S; Saviano M; Della Moglie R; Digilio G; Bracco C; Aloj L; Tarallo L; Pedone C; Morelli G
ChemMedChem; 2006 Sep; 1(9):997-1006. PubMed ID: 16915602
[TBL] [Abstract][Full Text] [Related]
11. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin antagonists: pharmacological and therapeutic potential.
Herranz R
Med Res Rev; 2003 Sep; 23(5):559-605. PubMed ID: 12789687
[TBL] [Abstract][Full Text] [Related]
13. Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
Schmitz F; Pratt DS; Wu MJ; Kolakowski LF; Beinborn M; Kopin AS
Mol Pharmacol; 1996 Aug; 50(2):436-41. PubMed ID: 8700154
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
Martín-Martínez M; Bartolomé-Nebreda JM; Gómez-Monterrey I; González-Muñiz R; García-López MT; Ballaz S; Barber A; Fortuño A; Del Río J; Herranz R
J Med Chem; 1997 Oct; 40(21):3402-7. PubMed ID: 9341915
[TBL] [Abstract][Full Text] [Related]
15. Intermolecular interactions between peptidic and nonpeptidic agonists and the third extracellular loop of the cholecystokinin 1 receptor.
Giragossian C; Sugg EE; Szewczyk JR; Mierke DF
J Med Chem; 2003 Jul; 46(16):3476-82. PubMed ID: 12877585
[TBL] [Abstract][Full Text] [Related]
16. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
McDonald IM; Austin C; Buck IM; Dunstone DJ; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Pether MJ; Spencer J; Wright PT; Adatia T; Bashall A
J Med Chem; 2006 Apr; 49(7):2253-61. PubMed ID: 16570921
[TBL] [Abstract][Full Text] [Related]
17. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists.
Henke BR; Aquino CJ; Birkemo LS; Croom DK; Dougherty RW; Ervin GN; Grizzle MK; Hirst GC; James MK; Johnson MF; Queen KL; Sherrill RG; Sugg EE; Suh EM; Szewczyk JW; Unwalla RJ; Yingling J; Willson TM
J Med Chem; 1997 Aug; 40(17):2706-25. PubMed ID: 9276016
[TBL] [Abstract][Full Text] [Related]
18. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
Dong M; Liu G; Pinon DI; Miller LJ
Biochemistry; 2005 May; 44(17):6693-700. PubMed ID: 15850403
[TBL] [Abstract][Full Text] [Related]
19. Purification, amino acid sequence, synthesis, and receptor selectivity of alligator gastrin.
Vigna SR; Elsey RM; Cheek AO; Faull KF; Reeve JR
Gen Comp Endocrinol; 1997 Nov; 108(2):316-26. PubMed ID: 9356227
[TBL] [Abstract][Full Text] [Related]
20. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
Arlander SJ; Dong M; Ding XQ; Pinon DI; Miller LJ
Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]